Oxford Cannabinoid Technologies: Phase 1 approval for lead chronic pain drug

Digital Asset Direct by Oxford Cannabinoid Technologies Holdings PLC

London, UK | May 24, 2023 10:59 AM Eastern Daylight Time

Proactive research analyst Daniel Appiah speaks to Thomas Warner after publishing a research note on Oxford Cannabinoid Technologies Holdings PLC (LSE:OCTP, OTCQB:OCTHF), entitled "Phase 1 approval for lead chronic pain drug." Oxford Cannabinoid Technologies Holdings CEO Clarissa Sowemimo-Coker recently told Proactive's Stephen Gunnion that Medicines and Healthcare products Regulatory Agency (MHRA) approval of a phase 1 trial for its lead pain relief drug candidate, OCT461201, represents a significant milestone for the company.

Contact Details

Proactive UK Ltd

+44 20 7989 0813

uk@proactiveinvestors.com